CN104958481A - Traditional Chinese medicine for treating rheumatoid arthritis (RA) due to yin deficiency and collateral heat - Google Patents
Traditional Chinese medicine for treating rheumatoid arthritis (RA) due to yin deficiency and collateral heat Download PDFInfo
- Publication number
- CN104958481A CN104958481A CN201510458057.0A CN201510458057A CN104958481A CN 104958481 A CN104958481 A CN 104958481A CN 201510458057 A CN201510458057 A CN 201510458057A CN 104958481 A CN104958481 A CN 104958481A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- rheumatoid arthritis
- radix
- traditional chinese
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 title claims abstract description 52
- 206010039073 rheumatoid arthritis Diseases 0.000 title claims abstract description 35
- 208000031971 Yin Deficiency Diseases 0.000 title abstract description 3
- 230000007812 deficiency Effects 0.000 claims description 27
- 238000011282 treatment Methods 0.000 claims description 27
- 206010037660 Pyrexia Diseases 0.000 claims description 20
- 241000533849 Gleditsia Species 0.000 claims description 13
- 241000522620 Scorpio Species 0.000 claims description 13
- 239000009490 scorpio Substances 0.000 claims description 13
- 210000000582 semen Anatomy 0.000 claims description 13
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 claims description 13
- 235000001892 vitamin D2 Nutrition 0.000 claims description 13
- 239000011653 vitamin D2 Substances 0.000 claims description 13
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 12
- 229940079593 drug Drugs 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 9
- 230000002757 inflammatory effect Effects 0.000 abstract description 6
- 235000013399 edible fruits Nutrition 0.000 abstract 3
- 241000049624 Alisma plantago-aquatica subsp. orientale Species 0.000 abstract 1
- 241000237528 Arcidae Species 0.000 abstract 1
- 229910021532 Calcite Inorganic materials 0.000 abstract 1
- 241000050051 Chelone glabra Species 0.000 abstract 1
- 244000286838 Eclipta prostrata Species 0.000 abstract 1
- 241000931143 Gleditsia sinensis Species 0.000 abstract 1
- 235000018142 Hedysarum alpinum var americanum Nutrition 0.000 abstract 1
- 240000006461 Hedysarum alpinum var. americanum Species 0.000 abstract 1
- 240000005779 Jasminum multiflorum Species 0.000 abstract 1
- 244000241838 Lycium barbarum Species 0.000 abstract 1
- 235000015459 Lycium barbarum Nutrition 0.000 abstract 1
- 235000015468 Lycium chinense Nutrition 0.000 abstract 1
- 240000005001 Paeonia suffruticosa Species 0.000 abstract 1
- 235000003889 Paeonia suffruticosa Nutrition 0.000 abstract 1
- 241000972673 Phellodendron amurense Species 0.000 abstract 1
- 241001522129 Pinellia Species 0.000 abstract 1
- 241000405414 Rehmannia Species 0.000 abstract 1
- 241000239226 Scorpiones Species 0.000 abstract 1
- 244000087639 Sophora tomentosa Species 0.000 abstract 1
- 241000913745 Spatholobus Species 0.000 abstract 1
- 244000178320 Vaccaria pyramidata Species 0.000 abstract 1
- 235000010587 Vaccaria pyramidata Nutrition 0.000 abstract 1
- 239000000853 adhesive Substances 0.000 abstract 1
- 230000001070 adhesive effect Effects 0.000 abstract 1
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 description 17
- 208000024891 symptom Diseases 0.000 description 8
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 206010062717 Increased upper airway secretion Diseases 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 231100000862 numbness Toxicity 0.000 description 4
- 230000008506 pathogenesis Effects 0.000 description 4
- 208000026435 phlegm Diseases 0.000 description 4
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 210000001503 joint Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 2
- 206010067868 Skin mass Diseases 0.000 description 2
- 208000005946 Xerostomia Diseases 0.000 description 2
- 206010048245 Yellow skin Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 206010013781 dry mouth Diseases 0.000 description 2
- 210000004247 hand Anatomy 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000010985 leather Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 210000000707 wrist Anatomy 0.000 description 2
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010051728 Bone erosion Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- 208000032912 Local swelling Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 206010036030 Polyarthritis Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 208000030428 polyarticular arthritis Diseases 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the technical field of medicines and in particular relates to a traditional Chinese medicine for treating rheumatoid arthritis (RA) due to yin deficiency and collateral heat. The traditional Chinese medicine comprises the following traditional Chinese medicines in parts by weight: 11-19 parts of prepared rhizome of adhesive rehmannia, 8-16 parts of common macrocarpium fruit, 11-19 parts of barbary wolfberry fruit, 11-19 parts of yerbadetajo herb, 11-19 parts of Chinese starjasmine stem, 8-16 parts of calcite, 8-16 parts of baical skullcap root, 8-16 parts of amur corktree bark, 8-16 parts of light yellow sophora root, 4-8 parts of scorpion, 8-16 parts of suberect spatholobus stem, 5-13 parts of cowherb seed, 4-8 parts of pinellia tuber, 2-4 parts of Chinese honeylocust fruit, 8-16 parts of ark shell, 4-8 parts of Indian buead, 4-8 parts of oriental waterplantain rhizome, 4-8 parts of tree peony bark and 4-8 parts of liquorice root. The inflammatory indicator level of RA can be obviously reduced, the functions of joints and the X-ray stage can be improved and the curative effects are definite by adopting the traditional Chinese medicine.
Description
Technical field
The invention belongs to medical art, be specifically related to a kind of Chinese medicine for the treatment of deficiency of YIN network pattern of fever rheumatoid arthritis.
Background technology
Rheumatoid arthritis (RA) is that a kind of antigen drives, cell-mediated and relevant to inherited genetic factors autoimmune disease, it is characterized in that chronic symmetry polyarthritis, gets involved the most common with both hands, wrist, knee joint, ankle and joints of foot.Patient can with extra-articular manifestations such as heating, anemia, subcutaneous nodule and lymphadenectasis.Multiple autoantibody can be had in serum to occur.Without correct deficiency of YIN network pattern of fever rheumatoid arthritis Chang Fanfu protracted course of disease for the treatment of finally because bone erosion causes joint deformity and afunction.The sickness rate of rheumatoid arthritis is ten thousand, and prevalence is.China adjusts Check deficiency of YIN network pattern of fever rheumatoid arthritis multiple in women through preliminary epidemiology.The ratio of men and women is 1:3, and can betide any age, onset peak in 30-50 year.
Although western medical treatment RA onset is very fast, can controls and relief of symptoms, delay disease progression, the obvious toxic and side effects of normal appearance; Chinese medicine determination for the treatment of based on pathogenesis obtained through differentiation of symptoms and signs, adjustment body function, strengthens and while after treatment effect, side effect is less.
At present, need to find the Chinese medicine being exclusively used in treatment deficiency of YIN network pattern of fever rheumatoid arthritis.
Summary of the invention
Technical problem to be solved by this invention avoids the weak point existing for above-mentioned prior art, a kind of Chinese medicine for the treatment of deficiency of YIN network pattern of fever rheumatoid arthritis is provided, this Chinese medicine obviously can reduce the inflammatory parameters level of rheumatoid arthrosis, improves function of joint and x-ray by stages, determined curative effect.
The present invention is achieved through the following technical solutions:
Treat a Chinese medicine for deficiency of YIN network pattern of fever rheumatoid arthritis, be made up of the Chinese medicine of following weight portion:
Radix Rehmanniae Preparata 11-19 part, Fructus Corni 8-16 part, Fructus Lycii 11-19 part, Herba Ecliptae 11-19 part, Caulis Trachelospermi 11-19 part, Mirabilitum crystallina 8-16 part, Radix Scutellariae 8-16 part, Cortex Phellodendri 8-16 part, Radix Sophorae Flavescentis 8-16 part, Scorpio 4-8 part, Caulis Spatholobi 8-16 part, Semen Vaccariae 5-13 part, Rhizoma Pinelliae 4-8 part, Fructus Gleditsia 2-4 part, Concha Arcae 8-16 part, Poria 4-8 part, Rhizoma Alismatis 4-8 part, Cortex Moutan 4-8 part, Radix Glycyrrhizae 4-8 part.
Preferably, the Chinese medicine of above-mentioned treatment deficiency of YIN network pattern of fever rheumatoid arthritis, is made up of the Chinese medicine of following weight portion:
Radix Rehmanniae Preparata 13-17 part, Fructus Corni 10-14 part, Fructus Lycii 13-17 part, Herba Ecliptae 13-17 part, Caulis Trachelospermi 13-17 part, Mirabilitum crystallina 10-14 part, Radix Scutellariae 10-14 part, Cortex Phellodendri 10-14 part, Radix Sophorae Flavescentis 10-14 part, Scorpio 5-7 part, Caulis Spatholobi 10-14 part, Semen Vaccariae 7-11 part, Rhizoma Pinelliae 5-7 part, Fructus Gleditsia 2.5-3.5 part, Concha Arcae 10-14 part, Poria 5-7 part, Rhizoma Alismatis 5-7 part, Cortex Moutan 5-7 part, Radix Glycyrrhizae 5-7 part.
Preferred, the Chinese medicine of above-mentioned treatment deficiency of YIN network pattern of fever rheumatoid arthritis, is made up of the Chinese medicine of following weight portion:
Radix Rehmanniae Preparata 15 parts, Fructus Corni 12 parts, Fructus Lycii 15 parts, Herba Ecliptae 15 parts, Caulis Trachelospermi 15 parts, Mirabilitum crystallina 12 parts, Radix Scutellariae 12 parts, Cortex Phellodendri 12 parts, Radix Sophorae Flavescentis 12 parts, Scorpio 6 parts, Caulis Spatholobi 12 parts, Semen Vaccariae 9 parts, the Rhizoma Pinelliae 6 parts, 3 parts, Fructus Gleditsia, Concha Arcae 12 parts, Poria 6, Rhizoma Alismatis 6 parts, Cortex Moutan 6 parts, 6 parts, Radix Glycyrrhizae.
The ratio of above weight proportion is through that science screening obtains, and for especial patient, as serious symptom or mild, fat or modest patient, can the proportioning of amount of corresponding adjustment composition, and increase or reduce being no more than 100%, drug effect is substantially constant.
The weight portion of said medicine, if in units of part, the normally consumption of 1 dose.
The indication of Chinese medicine of the present invention: be used for the treatment of deficiency of YIN network pattern of fever rheumatoid arthritis.
The taboo item of Chinese medicine of the present invention: the fasting for the treatment of period in a medicine is greasy, raw and cold, the smelling of fish or mutton, irritant and stodgy food.
The Chinese medicine related in prescriptions of Chinese medicine of the present invention all records in Chinese Pharmacopoeia 2010 editions.
RA belongs to the category of " rheumatoid arthritis " in Chinese medicine, its pathogenesis and deficiency of YIN network heat closely related.The hepatic and renal YIN deficiency is the pathologic basis of quasi-wind gateway " deficiency of YIN network heat syndrome ", and " meridians accumulation of heat " is the core of pathological change.Its total pathogenesis can be summarized as deficiency of YIN heat stagnation, wind-damp numbness, phlegm and blood stasis.Pathologic feature is deficiency in origin and excess in superficiality, and pathological factor is mainly the expectorant stasis of blood.The pathological changes initial stage is evil between flesh table, meridians, joint, therefore first sees disease, obstinate disease, pathogenic factor going from the exterior into the interior based on " the five body constituents numbness " of limbs all joints being painful, by dirty through entering, is formed difficult " syndromes caused by obstructed QI in five ZANG-organs " of healing.As shown as obstruction of heart-QI person except seeing arthralgia, be out of shape tetanic, color of the leather reddens, and the feel heat touched, hectic fever xerostomia, is also shown in the symptom of the heart-yin virtual loss such as palpitation and uneasiness, asthma, irregularly intermittent and regularly intermittent pulse outside urine yellow skin.Treatment is worked as with replenishing YIN and removing heat, phlegm reduction of blood circulation promoting, a surname's numbness dredging collateral.
Chinese prescription mechanism of the present invention is as follows:
Monarch drug: Radix Rehmanniae Preparata, Fructus Corni, Fructus Lycii, Herba Ecliptae merit are with tonifying liver kidney yin.
Ministerial drug: Radix Gentianae Macrophyllae, Herba Siegesbeckiae, Caulis Trachelospermi merit are with expelling wind-damp and clearing heat; Mirabilitum crystallina merit is with clearing away heat-fire; Radix Scutellariae, Cortex Phellodendri, Radix Sophorae Flavescentis merit are with heat clearing and damp drying.
Adjuvant drug: Scorpio, Caulis Spatholobi, Semen Vaccariae merit are with promoting blood circulation to remove obstruction in the collateral.The Rhizoma Pinelliae, Fructus Gleditsia, Concha Arcae merit with eliminating phlegm and softening indurated mass, blood stasis-eliminating and stagnation-dissipating.Poria, Rhizoma Alismatis, the anti-tonifying recipes of Cortex Moutan three medicine are grown greasy injuring one's stomach and are hindered spleen.
Make medicine: Radix Glycyrrhizae coordinating the actions of various ingredients in a prescription.
We's compatibility is reasonable, and all medicines share plays replenishing YIN and removing heat, phlegm reduction of blood circulation promoting altogether, the effect of a surname's numbness dredging collateral, the pathogenesis of the rheumatoid arthritis deficiency of YIN that links closely network heat syndrome, obviously can reduce the inflammatory parameters level of rheumatoid arthrosis, improve function of joint and x-ray by stages, determined curative effect, is worthy to be popularized.
Detailed description of the invention
Below in conjunction with specific embodiment, the present invention is further described, so that those skilled in the art more understands the present invention, but does not therefore limit the present invention.
Embodiment 1
Treat a Chinese medicine for deficiency of YIN network pattern of fever rheumatoid arthritis, each crude drug weight proportion is as follows:
Radix Rehmanniae Preparata 15g, Fructus Corni 12g, Fructus Lycii 15g, Herba Ecliptae 15g, Caulis Trachelospermi 15g, Mirabilitum crystallina 12g, Radix Scutellariae 12g, Cortex Phellodendri 12g, Radix Sophorae Flavescentis 12g, Scorpio 6g, Caulis Spatholobi 12g, Semen Vaccariae 9g, Rhizoma Pinelliae 6g, Fructus Gleditsia 3g, Concha Arcae 12g, Poria 6, Rhizoma Alismatis 6g, Cortex Moutan 6g, Radix Glycyrrhizae 6g.
Embodiment 2
Treat a Chinese medicine for deficiency of YIN network pattern of fever rheumatoid arthritis, each crude drug weight proportion is as follows:
Radix Rehmanniae Preparata 13g, Fructus Corni 14g, Fructus Lycii 13g, Herba Ecliptae 17g, Caulis Trachelospermi 13g, Mirabilitum crystallina 14g, Radix Scutellariae 10g, Cortex Phellodendri 14g, Radix Sophorae Flavescentis 10g, Scorpio 5g, Caulis Spatholobi 14g, Semen Vaccariae 7g, Rhizoma Pinelliae 7g, Fructus Gleditsia 2.5g, Concha Arcae 14g, Poria 5g, Rhizoma Alismatis 7g, Cortex Moutan 5g, Radix Glycyrrhizae 7g.
Embodiment 3
Treat a Chinese medicine for deficiency of YIN network pattern of fever rheumatoid arthritis, each crude drug weight proportion is as follows:
Radix Rehmanniae Preparata 17g, Fructus Corni 10g, Fructus Lycii 17g, Herba Ecliptae 13g, Caulis Trachelospermi 17g, Mirabilitum crystallina 10g, Radix Scutellariae 14g, Cortex Phellodendri 10g, Radix Sophorae Flavescentis 14g, Scorpio 7g, Caulis Spatholobi 10g, Semen Vaccariae 11g, Rhizoma Pinelliae 5g, Fructus Gleditsia 3.5g, Concha Arcae 10g, Poria 7g, Rhizoma Alismatis 5g, Cortex Moutan 7g, Radix Glycyrrhizae 5g.
Embodiment 4
Treat a Chinese medicine for deficiency of YIN network pattern of fever rheumatoid arthritis, each crude drug weight proportion is as follows:
Radix Rehmanniae Preparata 11g, Fructus Corni 16g, Fructus Lycii 11g, Herba Ecliptae 19g, Caulis Trachelospermi 11g, Mirabilitum crystallina 16g, Radix Scutellariae 8g, Cortex Phellodendri 16g, Radix Sophorae Flavescentis 8g, Scorpio 4g, Caulis Spatholobi 16g, Semen Vaccariae 5g, Rhizoma Pinelliae 8g, Fructus Gleditsia 2g, Concha Arcae 16g, Poria 4g, Rhizoma Alismatis 8g, Cortex Moutan 4g, Radix Glycyrrhizae 8g.
Embodiment 5
Treat a Chinese medicine for deficiency of YIN network pattern of fever rheumatoid arthritis, each crude drug weight proportion is as follows:
Radix Rehmanniae Preparata 19g, Fructus Corni 8g, Fructus Lycii 19g, Herba Ecliptae 11g, Caulis Trachelospermi 19g, Mirabilitum crystallina 8g, Radix Scutellariae 16g, Cortex Phellodendri 8g, Radix Sophorae Flavescentis 16g, Scorpio 8g, Caulis Spatholobi 8g, Semen Vaccariae 13g, Rhizoma Pinelliae 4g, Fructus Gleditsia 4g, Concha Arcae 8g, Poria 8g, Rhizoma Alismatis 4g, Cortex Moutan 8g, Radix Glycyrrhizae 4g.
Carried out clinical pharrnacokinetics test to Chinese medicine of the present invention, Details as Follows:
1. data and method
1.1 object of study
Choose 160 routine rheumatoid arthritis deficiency of YIN network heat syndrome patients.
1.2 Western medicine diagnose standards
Meet the standard of Americanism damp disease academic year revision:
(1) refuse to budge morning continuous 1 hour (>=6 weeks).
(2) more than 3 or 3 arthroncuss (>=6 weeks) are had.
(3) wrist, the palm refer to and proximal interphalangeal joint swollen (>=6 weeks).
(4) symmetry swollen joint (>=6 weeks).
(5) subcutaneous nodule is had.
(6) hands line changes (having the narrow of osteoporosis and joint space at least).
(7) rheumatoid factor positive (titre >1:32).
Possessing above more than 4 or 4 persons all diagnosable is rheumatoid arthritis.
1.3 TCM syndrome diagnostic criteria
Meet rheumatoid arthritis to wet the CM syndrome differentiation criterion of deficiency of YIN network heat syndrome: disease is seen: arthralgia, local swelling, or is out of shape tetanic, and color of the leather reddens, the feels heat touched, hectic fever xerostomia, soreness of the waist and knees, urine yellow skin, red tongue with thin fur or few tongue, light stripping, thready and rapid pulse.
1.4 inclusive criteria
1. meet doctor trained in Western medicine Diagnosis of Rheumatoid Arthritis standard, and meet the patient of traditional Chinese medical science deficiency of YIN network heat syndrome CM syndrome differentiation criterion simultaneously;
2. the age is between 18-65 years old, male or female;
3. informed consent, volunteers tested.
4. function of joint 1-3 level.
5. x-ray I-III phase by stages.
1.5 exclusion standard
(1) age is at under-18s or over-65s, the female patient of gestation and age of sucking;
(2) severe primary disease, the psychotics such as cardiovascular, cerebrovascular, liver, kidney and hemopoietic system is associated with;
(3) serious stomach or duodenal ulcer or rotten to the corn person is associated with;
(4) patient of severe joint deformity, afunction;
(5) other Patients with Rheumatic Diseases are associated with;
(6) the dialectical claimer of deficiency of YIN network heat syndrome is not met;
(7) arthrotrauma history person;
(8) to the not resistance to receptor of this medicine;
(9) function of joint 4 grades, the patient of x-ray IV phase;
1.6 Therapeutic Method
Give Chinese medicine of the present invention, prescription is as follows: Radix Rehmanniae Preparata 15g, Fructus Corni 12g, Fructus Lycii 15g, Herba Ecliptae 15g, Caulis Trachelospermi 15g, Mirabilitum crystallina 12g, Radix Scutellariae 12g, Cortex Phellodendri 12g, Radix Sophorae Flavescentis 12g, Scorpio 6g, Caulis Spatholobi 12, Semen Vaccariae 9g, Rhizoma Pinelliae 6g, Fructus Gleditsia 3g, Concha Arcae 12g, Radix Glycyrrhizae 6g.Be decocted in water for oral dose, day potion, sooner or later sub-service was a course for the treatment of with 2 weeks.
1.7 observation index
1. TCM syndrome integration;
2. main physical signs arthroncus degree, articular pain degree, grip;
3. inflammatory parameters: ESR, RF, CRP, x-ray are by stages etc.;
5. respectively rheumatoid arthritis clinical symptoms and sign classification and scoring, Chinese medicine syndrome integral are evaluated before and after treatment.
1.8 traditional Chinese medical science sign curative effect determinate standards
1. clinical recovery: tcm clinical practice symptom, sign disappear or substantially disappear, syndrome integral reduces >=95%
2. effective: tcm clinical practice symptom, sign are obviously improved, syndrome integral reduces >=70%
3. effective: tcm clinical practice symptom, sign all take a favorable turn, syndrome integral reduces >=30%
4. invalid: tcm clinical practice symptom, sign are all not improved or increase the weight of, syndrome integral reduces <30%.
Computing formula: nimodipine method: integration x100% before (before treatment the rear integration of integration-treatment)/treatment.
1.9 statistical analysis technique
Using statistics software carries out analytic statistics analysis.Enumeration data adopts X2 inspection, and measurement data adopts t inspection, with P<0.05, ranked data Bian rank test, represents that difference has statistical significance.
2. result
Inflammatory parameters change before and after 2.1 treatments
Front and back inflammatory parameters change treated by table 1
| Time | ESR | RF | CRP |
| Before treatment | 65.21±11.78 | 543.12±62.88 | 178.45±34.23 |
| After treatment | 10.22 ±3.67 | 87.12±14.56 | 26.15±7.34 |
After treatment, ESR, RF, CRP level is obviously improved before all comparatively treating, and difference has statistical significance (P<0.05); In table 1.
Before and after 2.2 treatments, function of joint classification and x-ray compare by stages
Treatment posterior joint functional classification and x-ray be all comparatively front obviously improvement for the treatment of by stages, and difference has statistical significance (P<0.05), in table 2.
2.3 TCM syndrome curative effects
160 routine patients, recovery from illness 81 example, effective 65 examples, effective 12 examples, invalid 2 examples, cure rate 50.6%, total obvious effective rate 91.3%, total effective rate 98.8%.
Claims (3)
1. treat a Chinese medicine for deficiency of YIN network pattern of fever rheumatoid arthritis, be made up of the Chinese medicine of following weight portion:
Radix Rehmanniae Preparata 11-19 part, Fructus Corni 8-16 part, Fructus Lycii 11-19 part, Herba Ecliptae 11-19 part, Caulis Trachelospermi 11-19 part, Mirabilitum crystallina 8-16 part, Radix Scutellariae 8-16 part, Cortex Phellodendri 8-16 part, Radix Sophorae Flavescentis 8-16 part, Scorpio 4-8 part, Caulis Spatholobi 8-16 part, Semen Vaccariae 5-13 part, Rhizoma Pinelliae 4-8 part, Fructus Gleditsia 2-4 part, Concha Arcae 8-16 part, Poria 4-8 part, Rhizoma Alismatis 4-8 part, Cortex Moutan 4-8 part, Radix Glycyrrhizae 4-8 part.
2. the Chinese medicine for the treatment of deficiency of YIN network pattern of fever rheumatoid arthritis according to claim 1, is characterized in that, be made up of the Chinese medicine of following weight portion:
Radix Rehmanniae Preparata 13-17 part, Fructus Corni 10-14 part, Fructus Lycii 13-17 part, Herba Ecliptae 13-17 part, Caulis Trachelospermi 13-17 part, Mirabilitum crystallina 10-14 part, Radix Scutellariae 10-14 part, Cortex Phellodendri 10-14 part, Radix Sophorae Flavescentis 10-14 part, Scorpio 5-7 part, Caulis Spatholobi 10-14 part, Semen Vaccariae 7-11 part, Rhizoma Pinelliae 5-7 part, Fructus Gleditsia 2.5-3.5 part, Concha Arcae 10-14 part, Poria 5-7 part, Rhizoma Alismatis 5-7 part, Cortex Moutan 5-7 part, Radix Glycyrrhizae 5-7 part.
3. the Chinese medicine for the treatment of deficiency of YIN network pattern of fever rheumatoid arthritis according to claim 3, is characterized in that, be made up of the Chinese medicine of following weight portion:
Radix Rehmanniae Preparata 15 parts, Fructus Corni 12 parts, Fructus Lycii 15 parts, Herba Ecliptae 15 parts, Caulis Trachelospermi 15 parts, Mirabilitum crystallina 12 parts, Radix Scutellariae 12 parts, Cortex Phellodendri 12 parts, Radix Sophorae Flavescentis 12 parts, Scorpio 6 parts, Caulis Spatholobi 12 parts, Semen Vaccariae 9 parts, the Rhizoma Pinelliae 6 parts, 3 parts, Fructus Gleditsia, Concha Arcae 12 parts, Poria 6, Rhizoma Alismatis 6 parts, Cortex Moutan 6 parts, 6 parts, Radix Glycyrrhizae.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510458057.0A CN104958481A (en) | 2015-07-30 | 2015-07-30 | Traditional Chinese medicine for treating rheumatoid arthritis (RA) due to yin deficiency and collateral heat |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510458057.0A CN104958481A (en) | 2015-07-30 | 2015-07-30 | Traditional Chinese medicine for treating rheumatoid arthritis (RA) due to yin deficiency and collateral heat |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104958481A true CN104958481A (en) | 2015-10-07 |
Family
ID=54212684
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510458057.0A Withdrawn CN104958481A (en) | 2015-07-30 | 2015-07-30 | Traditional Chinese medicine for treating rheumatoid arthritis (RA) due to yin deficiency and collateral heat |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104958481A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104983971A (en) * | 2015-07-30 | 2015-10-21 | 济南邦文医药科技有限公司 | Traditional Chinese medicine for treating dampness-heat blocking collateral type rheumatoid arthritis |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1342462A (en) * | 2000-09-08 | 2002-04-03 | 何兴峰 | Composite medicine for treating rheumatoid arthritis |
| CN1559496A (en) * | 2004-03-08 | 2005-01-05 | 马艳峰 | Chinese medicine preparation of removing obstruction in the channels for treating atrophic arthritis |
| CN102091316A (en) * | 2011-02-25 | 2011-06-15 | 黄相杰 | Traditional Chinese medicine for treating rheumatoid arthritis |
-
2015
- 2015-07-30 CN CN201510458057.0A patent/CN104958481A/en not_active Withdrawn
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1342462A (en) * | 2000-09-08 | 2002-04-03 | 何兴峰 | Composite medicine for treating rheumatoid arthritis |
| CN1559496A (en) * | 2004-03-08 | 2005-01-05 | 马艳峰 | Chinese medicine preparation of removing obstruction in the channels for treating atrophic arthritis |
| CN102091316A (en) * | 2011-02-25 | 2011-06-15 | 黄相杰 | Traditional Chinese medicine for treating rheumatoid arthritis |
Non-Patent Citations (1)
| Title |
|---|
| 周德生 等: "《中医名方全书 珍藏本 超值版》", 31 August 2012, 湖南科学技术出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104983971A (en) * | 2015-07-30 | 2015-10-21 | 济南邦文医药科技有限公司 | Traditional Chinese medicine for treating dampness-heat blocking collateral type rheumatoid arthritis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104587090A (en) | Medicine for treating rheumatoid arthritis | |
| CN102488879A (en) | Medicinal composition for treating rheumatism | |
| CN102294009A (en) | Chinese medicinal composition for treating rheumatoid arthritis | |
| CN118526548B (en) | Traditional Chinese medicine composition for treating sarcopenia of old people and preparation method and application thereof | |
| CN114588242B (en) | Pharmaceutical composition for treating rheumatoid arthritis | |
| CN104958481A (en) | Traditional Chinese medicine for treating rheumatoid arthritis (RA) due to yin deficiency and collateral heat | |
| CN110269914A (en) | It is a kind of to treat rheumatoid bone bi-syndrome Chinese medicine composition | |
| CN104983755A (en) | Application of pharmaceutical composition in preparation of drugs for treating osteoporosis | |
| CN103735647A (en) | Medicated wine for treating chronic infectious arthritis | |
| CN104958417A (en) | Traditional Chinese medicine for treating rheumatoid arthritis (RA) due to damp-heat blocking collaterals | |
| CN104958383A (en) | Traditional Chinese medicine for treating rheumatoid arthritis (RA) | |
| CN101590208B (en) | Medicament composition for treating rheumatoid arthritis, and preparation method thereof | |
| CN105194207A (en) | Traditional Chinese medicine composition and application thereof | |
| CN105998582A (en) | Preparation method of traditional Chinese medicinal composition for treating rheumatoid arthritis | |
| CN115814040B (en) | Traditional Chinese medicine composition for treating rheumatoid arthritis and preparation thereof | |
| CN116350731B (en) | Formula for clearing heat, removing dampness and relieving arthralgia as well as preparation and application thereof | |
| CN102836346B (en) | Traditional Chinese medicine for treating lumbar disc herniation | |
| CN104983971A (en) | Traditional Chinese medicine for treating dampness-heat blocking collateral type rheumatoid arthritis | |
| CN110548118B (en) | Traditional Chinese medicine compound for preventing and treating primary biliary cholangitis and preparation method and application thereof | |
| CN107088222A (en) | A kind of draft prescription for curing mainly knee joint osseous arthritis | |
| CN106729154A (en) | A kind of Chinese medicine for treating spleen-deficient non-inflammatory vaginal discharge diseases and its application | |
| CN104998079A (en) | Traditional Chinese medicine composition for treating rheumatoid arthritis | |
| CN104524152A (en) | Traditional Chinese medicine composition for treating rheumatoid arthritis and preparation method thereof | |
| CN105456657A (en) | Traditional Chinese medicine composition for treating female postmenopausal osteoporosis and preparation method of traditional Chinese medicine composition | |
| CN102652806A (en) | Traditional Chinese medicine for treating anaphylactic purple macula |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20151007 |